{"denoms":[{"counts":[{"groupId":"BG000","value":"350"},{"groupId":"BG001","value":"350"},{"groupId":"BG002","value":"700"}],"units":"Participants"}],"groups":[{"description":"Participants received an intravenous (IV) infusion of 10 milligrams per kilograms (mg/kg) of Avelumab along with BSC, on Day 1 and 15 of each 28 days treatment cycle, until confirmed disease progression, participant refusal, lost to follow up, unacceptable toxicity, or study termination by the sponsor, whichever occurred first. BSC was administered as per the treating physician. Participants were followed up until death, end of the study or withdrawal of consent, whichever comes first, regardless of initiation of new anti-cancer therapy.","id":"BG000","title":"Avelumab + Best Supportive Care (BSC)"},{"description":"As prescribed by the treating physician, participants received BSC which included treatment with antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management, until confirmed disease progression, participant refusal, lost to follow up, unacceptable toxicity, or study termination by the sponsor, whichever occurred first. Participants were followed up until death, end of the study or withdrawal of consent, whichever comes first, regardless of initiation of new anti-cancer therapy.","id":"BG001","title":"Best Supportive Care"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.52","value":"67.20"},{"groupId":"BG001","spread":"9.20","value":"67.7"},{"groupId":"BG002","spread":"9.40","value":"67.44"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"84"},{"groupId":"BG001","value":"75"},{"groupId":"BG002","value":"159"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"266"},{"groupId":"BG001","value":"275"},{"groupId":"BG002","value":"541"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"30"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"286"},{"groupId":"BG001","value":"298"},{"groupId":"BG002","value":"584"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"86"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"75"},{"groupId":"BG001","value":"81"},{"groupId":"BG002","value":"156"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"232"},{"groupId":"BG001","value":"238"},{"groupId":"BG002","value":"470"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"41"},{"groupId":"BG001","value":"31"},{"groupId":"BG002","value":"72"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"The full analysis set included all randomized participants."}